Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 701–800 of 1,004
COVID-19 Vaccine-Related Arthritis: A Descriptive Study of Case Reports on a Rare Complication
Dawoud, R., Haddad, D., Shah, V., Patel, V., Abbas, G., Guduru, S., Dakka, A., Kaushik, V., & Cheriyath, P. (2022) · Cureus · doi:10.7759/cureus.26702 · Cited by 10
“Discussion Since the emergence of COVID-19 in November 2019, tens of millions of cases have been reported globally [22].”
BackgroundWeaver, K. N., Zhang, X., Dai, X., Chen, W., Watkins, R. D., Adler, J., Dubinsky, M. C., Kastl, A., Bousvaros, A., Strople, J. A., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac138 · Cited by 10
Ali, M. D., Almadan, L. Z., Alghamdi, R. A., Alghamdi, A. S., Almarhoon, S. A., Hassan, Y. A., Ahmad, A., Ghosn, S. A., Banu, N., & Eltrafi, Z. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s374265 · Cited by 10
Batıbay, S., Ulucaköy, R. K., Günendi, Z., Fidan, I., Bozdayı, G., & Gogus, F. N. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01089-6 · Cited by 10
“Although having an inflammatory rheumatic disease (IRD) is an exclusion criterion in the efficacy and safety studies of vaccines, the American College of Rheumatology (ACR) recommended that patients with IRD be offered and receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Thomas…”
BackgroundSajadi, M. M., Myers, A., Logue, J., Saadat, S., Shokatpour, N., Quinn, J., Newman, M., Deming, M. E., Tehrani, Z. R., Magder, L. S., et al. (2022) · mSphere · doi:10.1128/msphere.00279-22 · Cited by 10
The coverage of medical injuries in company trial informed consent forms
Healy, D., Roux, A. G., & Dressen, B. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-220043 · Cited by 10
Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
Kim, S., & Seok, H. Y. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06676-1 · Cited by 10
“However, the safety and efficacy of these vaccines in patients with CNS demyelinating disease are still unclear as previous studies only involved healthy adults [4, 6] and excluded those on immunotherapy [5] or with chronic neurologic disease [2].”
ResultMahamad, S., Modi, D., Al-Samkari, H. T., Cuker, A. C., Despotovic, J. M., Italiano, J. E., Lambert, M. P., Lee, E., Rondina, M. T., Sholzberg, M., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.100097 · Cited by 10
Nowill, A. E., Caruso, M., & de Campos-Lima, P. O. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133225 · Cited by 12
“222 (119); BNT162b2 (9, 115); BNT162b2 Bivalent (119); AWcorna (152); AZD1222 (3, 5); Ad5-nCoV (127); Ad26.”
Optimal control and stability analysis of an age-structured SEIRV model with imperfect vaccination
Kumar, M., Abbas, S., & Tridane, A. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023646 · Cited by 10
Silva‐Moraes, V., Souquette, A. H., Sautto, G. A., Paciello, I., Antonelli, G., Andreano, E., Rappuoli, R., Teixeira‐Carvalho, A., & Ross, T. M. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300041 · Cited by 10
“…from severe disease and hospitalization, indicating a critical role of cellular immunity in disease protection (17, 18). mRNA vaccines elicit functional T cell immunity, with CD4 1 and CD8 1 T cell subsets contributing to protective immune responses and long-term immunological memory (5, 7, 9).”
BackgroundWaning effectiveness of mRNA COVID-19 vaccines against inpatient and emergency department encounters
Giannouchos, T. V., Hair, N. L., Olatosi, B., & Li, X. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300198 · Cited by 12
mRNA vaccines against infectious diseases and future direction
Aleem, M. T., Munir, F., Shakoor, A., & Gao, F. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112320 · Cited by 13
Optimal Control Applied to Vaccination and Testing Policies for COVID-19
Olivares, A., & Staffetti, E. (2021) · Mathematics · doi:10.3390/math9233100 · Cited by 12
Salmerón-Ríos, S., Zamora, E. B. C., Céspedes, A. A., Romero-Rizos, L., Sánchez-Jurado, P. M., Sánchez-Nievas, G., Mas-Romero, M., Sahuquillo, M. T. T., Señalada, J. J. B., Romero, A. M., et al. (2021) · Journal of The American Geriatrics Society · doi:10.1111/jgs.17620 · Cited by 10
Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection
Park, H.-S., Shapiro, J. R., Sitaras, I., Woldemeskel, B. A., Garliss, C. C., Dziedzic, A., Sachithanandham, J., Jedlicka, A., Caputo, C. A., Rousseau, K. E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155944 · Cited by 12
Willingness to receive COVID-19 vaccine booster doses for adults and their children in Vietnam
Chu, D.-T., Thi, H. V., Thi, Y. V. N., Nguyen, M., Bui, N.-L., Hoang, V., Nam, D. H., Do, D.-L., Than, V., & Al-Tawfiq, J. (2022) · Journal of Human Behavior in The Social Environment · doi:10.1080/10911359.2022.2046235 · Cited by 9
“The risk of children getting COVID-19 is lower than adults, but if they are not vaccinated, the chances of spreading the virus are significantly higher (Thomson, 2021).”
BackgroundThe Impact of COVID-19 and Vaccine on the Human Nervous System
Chen, F., Cao, P., Liu, H., & Cai, D. (2022) · Neuroendocrinology · doi:10.1159/000524234 · Cited by 10
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic
Chen, P., Shi, X., He, W., Zhong, G., Tang, Y., Wang, H., & Zhang, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2040330 · Cited by 10
“The follow-up surveys indicated that the vaccine sustains the efficacy of 91% against SARS-COV-2.”
BackgroundResultInfluentialCostantino, M., Sellitto, C., Conti, V., Corbi, G., Marongiu, F., Genovese, G., Moccia, G., Capunzo, M., Borrelli, A., Pagliano, P., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051408 · Cited by 10
Sutharattanapong, N., Thotsiri, S., Kantachuvesiri, S., & Wiwattanathum, P. (2022) · Vaccines · doi:10.3390/vaccines10040572 · Cited by 10
Leuva, H., Zhou, M., Bräu, N., Brown, S. T., Mundi, P. S., Rosenberg, T.-C. M., Luhrs, C. A., Bates, S. E., Park, Y. A., & Fojo, T. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.07.005 · Cited by 12
Smith, L., Sim, J., Sherman, S. M., Amlôt, R., Cutts, M., Dasch, H. K., Sevdalis, N., & Rubin, G. J. (2022) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2022.111104 · Cited by 10
“[11] Reported adverse effects for the Moderna vaccine were more severe following the second than following the first dose.”
Hookham, L., Lee, H. C., Patel, D. A., Coelho, M., Giglio, N., Doaré, K. L., & Pannaraj, P. S. (2022) · Vaccines · doi:10.3390/vaccines11010078 · Cited by 10
“Thomas, SJ [27] USA, Argentina, Brazil, South Africa, Germany, Turkey Sept 2021 BNT162b2 (PfizerBioNTech) RPCT 1–2–3 16 to 17 (stratified) 683 July 2020– Oct 2020 Against confirmed COVID-19 was 100% (58.”
BackgroundResultBürzle, O., Menges, D., Maier, J. D., Schams, D., Puhan, M. A., Fehr, J. S., Ballouz, T., & Frei, A. L. (2023) · npj Vaccines · doi:10.1038/s41541-023-00657-3 · Cited by 10
Quiroga, B., Soler, M. J., Ortíz, A., & de Sequera, P. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.04.005 · Cited by 10
COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies
Harris, C. E., Vijenthira, A., Ong, S. Y., Baden, L. R., Hicks, L. K., & Baird, J. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390778 · Cited by 11
Liu, Y., Sánchez‐Ovando, S., Carolan, L. A., Dowson, L., Khvorov, A., Hadiprodjo, A. J., Tseng, Y. Y., Delahunty, C., Khatami, A., Macnish, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.034 · Cited by 13
Chen, J., Pan, L., Lu, Y. Z., Zhang, T., Xu, D., Yan, S., & Ouyang, Z. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2276624 · Cited by 11
“16,72 Similar to Turkey, Saudi Arabia also conducted very little mRNA vaccine research in Period 1.”
Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence
Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 10
Klamer, T. A., Linschoten, M., & Asselbergs, F. W. (2022) · Netherlands Heart Journal · doi:10.1007/s12471-022-01677-9 · Cited by 11
Maltseva, M., Galipeau, Y., McCluskie, P. S., Castonguay, N., Cooper, C., & Langlois, M. (2025) · Vaccines · doi:10.3390/vaccines13040351 · Cited by 9
Zhang, Y., Li, J., Wang, Z., Kuang, Y., Li, S., & Wang, X. (2025) · Animal Diseases · doi:10.1186/s44149-025-00186-7 · Cited by 9
“…Hepatic accumulation: Clinical data reveal that 10–20% of intramuscularly administered LNPs accumulate in the liver, contributing to systemic adverse events (e.g., fever and injection site pain) (Di et al. 2022, Walsh et al. 2020, Chen, Li, et al. 2022a, b, Thomas et al. 2021, Jackson et al. 2020).”
OpenSAFELY: Effectiveness of COVID-19 Vaccination in Children and Adolescents
Andrews, C. D., Parker, E. P. K., Horne, E. M. F., Walker, V. M., Palmer, T., Schaffer, A. L., Green, A. C. A., Curtis, H. J., Walker, A. J., Bridges, L., et al. (2025) · Epidemiology · doi:10.1097/ede.0000000000001908 · Cited by 9
Heftdal, L. D., Schultz, M., Lange, T., Knudsen, A. D., Fogh, K., Hasselbalch, R. B., Linander, C. B., Kallemose, T., Bundgaard, H., Grønbæk, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac012 · Cited by 9
Georgakopoulou, V., Vlachogiannis, N. I., Basoulis, D., Eliadi, I., Georgiopoulos, G. A., Karamanakos, G., Makrodimitri, S., Samara, S., Triantafyllou, M., Voutsinas, P., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071810 · Cited by 9
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M. W., Cooper, D., Muik, A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00462-4 · Cited by 9
Self-citationAharoni, M., Leader, A., Shochat, T., Raanani, P., & Spectre, G. (2022) · Platelets · doi:10.1080/09537104.2022.2071856 · Cited by 9
Thotsiri, S., Sittiudomsuk, R., Sutharattanapong, N., Kantachuvesiri, S., & Wiwattanathum, P. (2022) · Vaccines · doi:10.3390/vaccines10101690 · Cited by 9
Nanotechnologically Relevant Aspects of COVID-19 Vaccines
Batley, R. J., & Chandra, S. (2023) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1501007 · Cited by 9
Guo, B., Li, H.-B., & Yang, L. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.049 · Cited by 9
Rojas-Botero, M. L., Fernández-Niño, J. A., Arregocés-Castillo, L., Palacios-Clavijo, A. F., Pinto-Álvarez, M., & Gómez, F. R. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001845 · Cited by 10
Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials
Zyoud, S. H. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01254-3 · Cited by 11
Hurtado-Morillas, C., Martínez‐Rodrigo, A., Orden, J. A., de Urbina-Fuentes, L., Mas, A., & Domínguez‐Bernal, G. (2024) · Animals · doi:10.3390/ani14040605 · Cited by 9
“In this context, in parallel to the use of adjuvants, nanotechnology has introduced innovative possibilities for designing vaccine delivery systems against various infectious diseases, including leishmaniosis [19–21].”
BackgroundAyaz, H., Çelik, M. H., Koytak, H. Z., & Yanik, I. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308122 · Cited by 9
Beck, E. C., Georgieva, M. V., Wang, W., Gómez-Liévano, A., Wang, H., Gao, Y., Kopel, H., Bausch-Jurken, M. T., Patterson‐Lomba, O., Mu, F., et al. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2466726 · Cited by 9
“The searches yielded six studies with evidence on BNT162b2 that were assessed for suitability of an unanchored ITC: Polack et al. 8 , Thomas et al. 37 , Frenck et al. 38 , Moreira et al. 39 , Zou et al. 40 , and Gayed et al. 41 .”
Jahn, M., Korth, J., Dorsch, O., Anastasiou, O. E., Krawczyk, A., Brochhagen, L., van de Sand, L., Sorge-Hädicke, B., Tyczynski, B., Witzke, O., et al. (2022) · Vaccines · doi:10.3390/vaccines10020327 · Cited by 9
Walach, H., Klement, R. J., & Aukema, W. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.35 · Cited by 9
Berning, P., Huang, L., Razavi, A. C., Boakye, E., Osuji, N., Stokes, A., Martin, S. S., Ayers, J. W., Blaha, M. J., & Dzaye, O. D. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884211 · Cited by 10
A SARS-CoV-2 outbreak associated with vaccine breakthrough in an acute care hospital
Park, S. Y., Kim, T. H., Lee, E. J., Loeb, M. B., Jeong, Y. S., Kim, J. H., Oh, S. M., Cheong, S., Park, H., Jo, S., et al. (2022) · American Journal of Infection Control · doi:10.1016/j.ajic.2022.05.010 · Cited by 9
“9) 0 0 Duration of hospitalization/isolation, days 9 (8-10) 13 (9-19) 9 (6-11) .”
Vega‐Magaña, N., Muñóz-Valle, J. F., Rodríguez, M. P., Segura, O. V., Pereira-Suárez, A. L., Hernández‐Bello, J., & García‐Chagollán, M. (2022) · Vaccines · doi:10.3390/vaccines10071117 · Cited by 9
“When vaccine efficacy was evaluated in clinical trials, they excluded individuals with a prior diagnosis of COVID-19 [6,25]; therefore, little is known about how mRNA vaccine responses behave following a previous natural infection.”
BackgroundKatz, J., Labilloy, A., & Lee, A. (2022) · BMC Pediatrics · doi:10.1186/s12887-022-03561-2 · Cited by 9
Zhao, J., Zhu, J., Huang, C., Zhu, X., Zhu, Z., Wu, Q., & Yuan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035151 · Cited by 9
Fulminant Myocarditis and Acute Appendicitis after COVID-19 Vaccination
Kawano, H., Yamamoto, N., Kurohama, H., Okano, S., Kurobe, M., Honda, T., Akashi, R., Yonekura, T., Ikeda, S., Izumikawa, K., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0680-22 · Cited by 9
“Several severe acute respiratory coronavirus 2 (SARSCoV-2) vaccines have proven safe and efficacious in the prevention of its infection (1-3).”
Temtanakitpaisan, Y., Saengnipanthkul, S., Sarakosol, N., Maskasame, S., Mongkon, S., Buranrat, B., Thammawat, S., Patamatamkul, S., & Nernsai, P. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100242 · Cited by 9
Recent advances of nanotechnology in COVID 19: A critical review and future perspective
Chaudhary, K. R., Kujur, S., & Singh, K. (2022) · OpenNano · doi:10.1016/j.onano.2022.100118 · Cited by 14
Sung, S., Jenny, L. A., Chang, Y., Wang, N., & Liu, P. (2023) · Vaccines · doi:10.3390/vaccines11020365 · Cited by 9
“The four categories of SARS-CoV-2 vaccines include mRNA vaccines, which deliver genetic code through lipid nanoparticles (e.g., BNT162b2, Pfizer-BioN-Tech [1], mRNA-1273 and Moderna [2]), protein subunit vaccines, which extract short fragments of proteins from inactivated diseasecausing microorganisms (e.g., NVX-CoV23…”
BackgroundGillot, C., Bayart, J., Closset, M., Cabo, J., Maloteau, V., Dogné, J., Douxfils, J., & Favresse, J. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0134 · Cited by 10
OECD (2021) · Health at a glance · doi:10.1787/8b492d7a-en · Cited by 21
Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV
Marchitto, L., Chatterjee, D., Ding, S., Gendron‐Lepage, G., Tauzin, A., Boutin, M., Benlarbi, M., Medjahed, H., Sylla, M., Lanctôt, H., et al. (2023) · Viruses · doi:10.3390/v15102004 · Cited by 9
Hernández‐Ávila, M., Ortíz‐Brizuela, E., Tamayo‐Ortiz, M., Zepeda‐Tello, R., Gutiérrez-Díaz, H., Cordera, D. B. S., Vieyra-Romero, W. I., Real-Ornelas, G. A., Méndez-Aranda, M., & Gómez, A. H. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100612 · Cited by 10
Health Care Access and COVID-19 Vaccination in the United States: A Cross-Sectional Analysis
Guzman, C. D., Thomas, C. A., Wiwanto, L., Hu, D., Henriquez-Rivera, J. A., Gage, L., Perreault, J. C., Harris, E., Rastas, C., McCormick, D., et al. (2024) · Medical Care · doi:10.1097/mlr.0000000000002005 · Cited by 9
Vaccination and variants: Retrospective model for the evolution of Covid-19 in Italy
Fierro, A., Romano, S., & Liccardo, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265159 · Cited by 11
“4, 1], the time of appearance of the new variant, tvar, in the range [65, 105] and the time regulating the speed in the spreading of the new variant, τvar, in the range [10, 50] (Fig 5), the total number of detected cases at the final day of simulation varies less than 1%.”
BackgroundKvist‐Hansen, A., Pérez‐Alós, L., Al-Sofi, R. F., Heftdal, L. D., Hamm, S. R., Møller, D. L., Pries‐Heje, M. M., Fogh, K., Hansen, C. B., Hasselbalch, R. B., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad023 · Cited by 9
Covid-19: Researchers face wait for patient level data from Pfizer and Moderna vaccine trials
Block, J. (2022) · BMJ · doi:10.1136/bmj.o1731 · Cited by 9
Scholaert, M., Peries, M., Braun, E. J., Martin, J.-C., Serhan, N., Loste, A., Bruner, A., Basso, L., Chaput, B., Merle, E., et al. (2024) · Allergy · doi:10.1111/all.16273 · Cited by 8
“By calculating a Pearson correlation heatmap, we assessed the correlation between the transcriptomic profiles of day 0, 3, 5, and 10.”
BackgroundMethodBioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety
Alkhalil, E., Jarad, B., Saleh, T. A., Aldarwish, W., & Joujeh, D. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.292 · Cited by 8
“The vaccine has shown an efficacy of 91.3% against COVID-19 after 6 months of follow-up among participants without prior SARS-CoV-2 infection [91].”
InfluentialCirculating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus
Mamais, I., Malatras, A., Papagregoriou, G., Giallourou, N., Kakouri, A. C., Karayiannis, P., Koliou, M., Christaki, E., Nikolopoulos, G. K., & Deltas, C. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245882 · Cited by 8
Understanding COVID-19 Vaccines Today: Are T-cells Key Players?
Shafqat, A., Arabi, T. Z., Sabbah, B. N., Abdulkader, H. S., Shafqat, S., Razak, A., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Vaccines · doi:10.3390/vaccines10060904 · Cited by 8
Lorent, D., Nowak, R., Luwański, D., Pisarska-Krawczyk, M., Figlerowicz, M., & Zmora, P. (2022) · Vaccines · doi:10.3390/vaccines10101576 · Cited by 8
Kandeel, A., Fahim, M., Deghedy, O., Alim, W., Fattah, M. A., Afifi, S., Mohsen, A., & Abdelghaffar, K. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08097-z · Cited by 8
Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)
McLeod, C., Ramsay, J. A., Flanagan, K. L., Plebanski, M., Marshall, H. S., Dymock, M., Marsh, J., Estcourt, M. J., Wadia, U. D., Williams, P. C. M., et al. (2023) · Trials · doi:10.1186/s13063-023-07225-z · Cited by 8
Persson, G., Restori, K. H., Emdrup, J. H., Schussek, S., Klausen, M. S., Nicol, M. J., Katkere, B., Rønø, B., Kirimanjeswara, G. S., & Sørensen, A. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166546 · Cited by 8
“This, combined with waning vaccine-induced antibody levels over time (16–18), means that SARS-CoV-2 VOCs and other zoonotic novel coronaviruses continue to pose a threat (4, 19).”
BackgroundBellavite, P., Donzelli, A., & Isidoro, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237291 · Cited by 8
“…significant errors in the assessment of the risk/benefit ratio of vaccines, precisely in those categories characterized by greater fragility [1,140,141], as has been shown in a recent post-licensure study where the risk for all-causes of mortality (also accounting for underlying illnesses)…”
Liu, J., Wang, L., Kurtesi, A., Budylowski, P., Potts, K. G., Menon, H., Tan, Y., Samaan, P., Liu, X., Wang, Y., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01062-8 · Cited by 8
Vaccines for preventing infections in adults with haematological malignancies
Zorger, A.-M., Hirsch, C., Baumann, M., Feldmann, M., Bröckelmann, P. J., Mellinghoff, S. C., Monsef, I., Skoetz, N., & Kreuzberger, N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015530.pub2 · Cited by 8
Papadopoulos, D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Evangelakou, Z., Malandrakis, P., Manola, M. S., Gianniou, D. D., Kastritis, E., Trougakos, I. P., Dimopoulos, M. A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020204 · Cited by 9
“However, prot ction against COVID19, particularly against severe diseas , remains unchanged compared with unvacc nated indiv duals [16,25].”
BackgroundInfluentialCai, J., Yang, J., Deng, X., Peng, C., Chen, X., Wu, Q., Liu, H., Zhang, J., Zheng, W., Zou, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2063073 · Cited by 9
Case of reactive sacroiliitis possibly induced by an mRNA coronavirus disease vaccine
Roux, N., Poussing, S., & Maurier, F. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-249063 · Cited by 8
Grikscheit, K., Rabenau, H. F., Ghodratian, Z., Widera, M., Wilhelm, A., Toptan, T., Hoehl, S., Layer, E., Helfritz, F., & Ciesek, S. (2022) · Vaccines · doi:10.3390/vaccines10071163 · Cited by 9
“However, antibodies directed against SARS-CoV-2 are produced in varying quality and quantity after vaccination or recovery and these levels decrease over time [5].”
BackgroundDivergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS
Forte, E., Soye, B. J. D., Melani, R. D., Hollas, M. A. R., Kafader, J. O., Sha, B. E., Schneider, J. R., & Kelleher, N. L. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00514 · Cited by 8
Parn, S., Savsani, K., & Dakshanamurthy, S. (2022) · ImmunoInformatics · doi:10.1016/j.immuno.2022.100020 · Cited by 8
“They also confer a long-lasting immune response, superior to the relatively short-lived mRNA vaccines, which have shown to decline after six months of vaccination [49].”
BackgroundDavidson, G., Fahlman, A., Mereu, E., Ruiz-Martín, C., Wainer, G., Dobias, P., & Rempel, M. (2023) · SIMULATION · doi:10.1177/00375497231152458 · Cited by 10
“51 Three classes of vaccination status for individuals exist concurrently within this model: unvaccinated, vaccinated with dose 1 only, and vaccinated with two doses.”
BackgroundMethodEfetividade das vacinas da COVID-19 e disseminação do vírus: revisão sistemática
de Medeiros, G. Q., de Barros, V. N., Guesser, V. M., de Paiva, K. M., & Haas, P. (2023) · Revista Neurociências · doi:10.34024/rnc.2023.v31.14806 · Cited by 12
Palalay, H., Vyas, R., & Tafuto, B. A. (2023) · World Journal of Meta-Analysis · doi:10.13105/wjma.v11.i5.167 · Cited by 10
Mueller-Enz, M., Woopen, C., Rahbani, G. K. A., Haase, R., Dunsche, M., Ziemssen, T., & Akgün, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1081933 · Cited by 8
Semenzato, L., Botton, J., Vu, S. L., Jabagi, M.-J., Cuenot, F., Drouin, J., Dray‐Spira, R., Weill, A., & Zureik, M. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad460 · Cited by 10
“However, an upsurge of severe COVID-19 has been observed in vaccinated populations and might be linked to a decline in vaccine effectiveness over time [5] and/or the emergence of new variants.”
BackgroundCherry, N., Adisesh, A., Burstyn, I., Charlton, C. L., Chen, Y., Durand-Moreau, Q. V., Labrèche, F., Ruzycki, S. M., Turnbull, L., Zadunayski, T., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.052 · Cited by 9
COVID-19 vaccine acceptance and its associated factors in the Western Pacific Region
Jin, S., Lin, L. K., Larson, H. J., & Cook, A. R. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100840 · Cited by 9
Severe Acute Respiratory Syndrome Coronavirus‐2
Slev, P. R. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch54 · Cited by 8
COVID-19 herd immunity v. learning to live with the virus
Madhi, S. A. (2021) · South African Medical Journal · doi:10.7196/samj.2021.v111i9.16005 · Cited by 9
Clinical trial research on COVID-19 in Germany – a systematic analysis
Hirt, J., Rasadurai, A., Briel, M., Düblin, P., Janiaud, P., & Hemkens, L. G. (2021) · F1000Research · doi:10.12688/f1000research.55541.1 · Cited by 8
Waning anti-SARS-CoV-2 neutralizing antibody in CoronaVac-vaccinated individuals in Indonesia
Harapan, H., Royan, H. A., Tyas, I. I., Nadira, A., Abdi, I. F., Anwar, S., Husnah, M., Ichsan, I., Pranata, A., Mudatsir, M., et al. (2022) · F1000Research · doi:10.12688/f1000research.109676.1 · Cited by 8
“Reduction in the level of protective antibody might be due to the decreased NAb titres as waning antibody titres have been reportedly correlated with reduced protection over time.(12,25,35) This remarkable reduction in the titre of SARS-CoV-2 NAb anti-SRBD and its decline in protective level might indicate the need fo…”
Nohl, A., Brune, B., Weichert, V., Standl, F., Stang, A., & Dudda, M. (2022) · Vaccines · doi:10.3390/vaccines10030411 · Cited by 9
Stirrup, O., Krutikov, M., Tut, G., Palmer, T., Bone, D., Bruton, R. K., Fuller, C., Azmi, B., Lancaster, T., Sylla, P., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac146 · Cited by 8
“Vaccine effectiveness in the general population has been demonstrated for at least six months following second dose administration[3,4].”
Reliably Assessing Duration of Protection for Coronavirus Disease 2019 Vaccines
Lin, D.-Y., Zeng, D., Gu, Y., Krause, P. R., & Fleming, T. R. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac139 · Cited by 8
“Owing to the crossover of placebo recipients to the vaccine arm, phase 3 trials have provided efficacy information only for approximately 6 months after dose 2 [1, 2], although it is possible to recover placebo-controlled VE approximately 6 months after crossover under certain assumptions [10, 13, 14].”
Panìco, A., Lobreglio, G., Bagordo, F., Zizza, A., Donno, A. D., Rosato, C., Lazzari, R., Chicone, M., Indino, F., Recchia, V., et al. (2022) · Vaccines · doi:10.3390/vaccines10060862 · Cited by 8
“BNT162b2, developed by Pfizer/BioNTech, is a lipid nanoparticle formulated nucleoside-modified messenger RNA (mRNA), encoding the SARS-CoV-2 spike (S) protein, stabilized in the prefusion conformation [4].”
BackgroundTakahashi, W., Mizuno, T., Hara, K., Ara, Y., Hurutani, R., Agatsuma, T., & Fujimori, M. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9699-22 · Cited by 8
“o, n (%) 106 42 (40) 14 (13) 51 (48) 53 (50) †”
Background
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.